key: cord-0303475-yasb7ydz
authors: Ali, H.; Al-Terki, A.; Sindhu, S.; Alahmad, B.; Hammad, M.; Al-Sabah, S.; Alghounaim, M.; Jamal, M. H.; Aldei, A.; Mairza, M. J.; Husain, M.; Devarajan, S.; Ahmad, R.; Cherian, P.; Alkhairi, I.; Alkandari, A.; Abubaker, J.; Abu-farha, M.; Al-Mulla, F.
title: Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination
date: 2021-07-26
journal: nan
DOI: 10.1101/2021.07.23.21261042
sha: 0bfd9d3f123aab5ae304950939594020ab7b3e82
doc_id: 303475
cord_uid: yasb7ydz

The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people that took two doses of BNT162b2 (Pfizer-BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. Their levels were 154{+/-}49.1 vs. 138{+/-}59.4BAU/mL for IgG and 87.1{+/-}11.6 vs. 79.7{+/-}19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95%CI: -27.08 to -0.64BAU/ml, p=0.041) less IgG antibodies and 4.42% (95%CI: -8.53 to -0.32%, p=0.036) less neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity.

Introduction 90 COVID-19 pandemic has affected people worldwide to unprecedented proportions, even more 91 severely affecting the people with type-2 diabetes mellitus (T2DM) and/or those with other risk 92 factors for developing COVID-19 related complications. To date, more than 190 million people 93 worldwide have been diagnosed with COVID-19, with an overall prevalence rate of at least 2% (1) . 94

Although, mortality rates are generally lower (2.2%), the presence of preexisting health conditions 95 such as T2DM, hypertension, cardiovascular disease, and metabolic syndrome may contribute to 96 increased case fatality rates up to 10% (2-4). A myriad of factors may contribute to increased 97 susceptibility of T2DM patients for developing COVID-19 complications, including impaired 98 innate/adaptive immunity, after the onset of a state of chronic, low-grade inflammation called 99 metabolic inflammation. As a result, upon antigen exposure, the obesity-related chronic inflammation 100 may impair macrophage activation and blunt the mechanisms of pro-inflammatory and/or innate 101 cytokine production (5; 6). This altered, obesogenic milieu may partly explain the presence of 102 antiviral-resistance and vaccine escape mechanisms in obese and/or T2DM populations. Moreover, B 103 and T cell responses are compromised in obese and more so in obese T2DM people (7). The 104 unfavorable hormone environment also primes for immune response dysregulation (8). Typically, 105 obese T2DM people may have defective innate/adaptive immunity, resulting from the enhanced 106 production of several pro-inflammatory cytokines/chemokines like TNF-α, IFN-γ, IL-1β, IL-12, IL-107 18, RANTES, MCP-1 and IL-6 (9). Indeed, all these bioactive inflammatory proteins are also the 108 factors that have been associated with an increased susceptibility for developing COVID-19 109 complications (10; 11). 110 Driven by sheer urgency, COVID-19 vaccines have been developed at a phenomenal speed. One of 111 the most-widely used vaccines is known as BNT162b2 (Pfizer-BioNTech) which is an mRNA-based 112 COVID-19 vaccine that comprises of the nucleoside-modified mRNA (modRNA sequence of 4,284 113 nucleotides) encoding a mutated form (bases 103-3879) of the full-length spike (S) protein 114 (peplomer) of SARS-CoV-2 stabilized in its prefusion conformation as an antigen or immunogenic 115 molecule encapsulated in lipid nanoparticles that act as adjuvants (12). The vaccine is administered 116 as two shots, intramuscularly, given three weeks apart and has been shown to offer protection by 117 triggering an immune response against infection by the SARS-CoV-2 spike protein. Since 118 BNT162b2 vaccine delivers mRNA encoding only for SARS-CoV-2 spike protein, the expected 119 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint elicited response is production of anti-S-RBD immunoglobulin G (IgG), IgM, and IgA isotypes, with 120 neutralization potential of inhibiting the RBD binding to ACE2 cognate receptor (13 

After signing the consent form, a venous blood sample was collected in Vacutainer EDTA tubes. The 144 blood was then centrifuged at 400 × g for 10 min at room temperature to isolate plasma. Plasma 145 samples were then aliquoted and stored at −80°C until the assays were performed. 146

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint Plasma levels of SARS-CoV-2-specific IgG antibodies were detected using enzyme-linked 148 immunosorbent assay (ELISA) kit (SERION ELISA agile SARS-CoV-2 IgG SERION Diagnostics,  149 Würzburg, Germany), following the manufacturer's instructions. Briefly, plasma samples were 150 thawed at room temperature and centrifuged for 5 min at 10,000 ×g at 4°C for sample clarification 151 and removal of residual cells or platelets. For assay, samples were diluted 100× using sample diluent 152 provided with the kit. Then, 100µL of controls, serum cutoffs (provided in the kit) and samples were 153 transferred into the designated wells and incubated for 60 min at 37˚C in a humid chamber. 154

Following incubation, plates were washed 4× with 1× wash buffer and 100µL of antibody-specific 155 enzyme conjugate was added into each well. The plate was then incubated for 30 min at 37˚C in 156 humid chamber and later washed 4× as before. Next, the chromogenic substrate (TMB solution) was 157 added into each well and incubated for 30 min at 37˚C under humidity. Finally, the reaction was 158 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint 180 181

We provide summary descriptive analysis using mean, median, standard deviation and interquartile 183 range as appropriate. We fitted generalized additive linear models with plasma IgG levels and 184 neutralizing antibodies as the dependent variables and T2DM status (yes/no), hypertension (yes/no), 185 BMI (categorical: <25, 25-30, and >30 kg/m 2 ), age, gender, previous COVID-19 infection (yes/no), 186 comorbidity score (sum score of equal weight for heart disease, stroke, chronic obstructive 187 pulmonary disease, asthma, obstructive sleep apnea, chronic kidney disease, bleeding disorders and 188 other chronic diseases), and duration since receiving the second vaccine dose as the independent 189 variables. We fitted penalized splines for the two continuous variables age and duration since second 190 dose to account for non-linearity using restricted maximum likelihood (REML) estimation. Penalized 191 splines are smoothing nonparametric terms that can maximize the goodness-of-fit by cross-validation 192 and a penalty term for over-and under-fitting. We reported effect estimates with 95% confidence 193 intervals interpreted as change in average IgG and neutralizing levels after adjustment. 194

In an additional post-hoc analysis, we also explored interaction analyses looking into the effects of 195 being diabetic across age, gender, BMI, and hypertension categories on the circulating IgG levels. 196

We fitted stratified adjusted models to estimate the change in IgG levels comparing diabetics to non-197 diabetics. We then included an interaction term between diabetes status and the other variable of 198 interest to examine the Wald-test p-value for statistical significance. All analyses were done in R 199 software version 3.3.1 (R Foundation for Statistical Computing), penalized splines were implemented 200 in generalized additive models using the mgcv package. A p-value of less than 0.05 was considered to 201 indicate statistical significance. 202 3

Results 203

This study included a total of 262 participants;181 non-diabetics and 81 people diagnosed with 205 T2DM. Of these 262 individuals, 193 were normotensive and 69 were hypertensive. Subdividing 206 based on body mass index (BMI), 65 people had a BMI less than 25 kg/m 2 , 117 people had a BMI 207 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint between 25-30 kg/m 2 and 74 had a BMI higher than 30 kg/m 2 (BMI information for 6 individuals 208 was not available). This cohort included 126 females and 136 males (Table.1 Figure 1A) . Similarly, strong SARS-CoV-2 neutralizing 218 antibody levels were overall observed in our study cohort; however, neutralizing antibody levels 219

were also significantly lower in people with T2DM (79.7±19.5%) compared to those without T2DM 220 (87.1±11.6%) ( Figure 1B) . Clinical characteristics and serological findings in the studied population 221 stratified by T2DM status are summarized in (Table 1) . 222

After adjustment to potential confounders, on average, people with TD2M had 13.86 BAU/ml (95% 223 CI: -27.08 to -0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: -8.53 to -0.32%, 224 p=0.036) less neutralizing antibodies than non-diabetics ( Table 2) . 225

Obesity levels also did not significantly affect the levels of SARS-CoV-2 IgG and neutralizing 227 antibodies. The population was divided into normal weight, overweight and obese based on BMI 228 measurements. SARS-CoV2 IgG antibody levels in people with normal weight, overweight, and 229 obesity were 153±47.6 BAU/mL, 147.0±53.4 BAU/mL and 148.0±56.7 BAU/mL, respectively 230 ( Figure 1C) . Similarly, SARS-CoV2 neutralizing antibody levels were also comparable in our study 231 population and the levels in people with normal weight, overweight, and obesity were 86.3±12.8%, 232 84.3±16.6%, and 84.6±13.6%, respectively ( Figure 1D) . Obesity status did not show a statistically 233 significant difference in regression analyses ( Table 2) . 234

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint Next, we found that the circulating levels of SARS-CoV2 IgG antibodies were comparable between 236 people with or without hypertension. In people with hypertension, SARS-CoV2 IgG antibody levels 237

were relatively lower (144±54.8 BAU/mL) compared to those without hypertension (151±52.2 238 BAU/mL) ( Figure 1E) . Similarly, neutralizing antibody levels also differed between people with 239 hypertension and those without hypertension (81.7±17.3% vs 85.9± 13.8%) ( Figure 1F ). After 240 adjustment to potential confounders, the differences in humoral immunity by hypertension status 241 remained statistically non-significant ( Table 2) . 242

and Age 244

Circulating levels of SARS-CoV2 IgG antibodies were not significantly different when compared 245 between male and female (p=0.548) ( Table 2) . Overall, females had a higher SARS-CoV2 IgG 246 antibody level of 154.0±50.0 BAU/mL compared to 144.0±55.2 BAU/mL in male ( Figure 1G) . 247

Similarly, neutralizing antibody levels also differed non-significantly (p=0.865) ( Table 2) between 248 female and male, which were 85.9±13.5% vs 83.8± 16.0%, respectively ( Figure 1H) . Interestingly, 249 those with the previous COVID-19 infection had higher IgG and neutralizing antibody levels ( Figure  250 2) and a net average increase of 38.50 BAU/ml IgG (95% CI: 23.05 to 53.96 BAU/ml, p<0.001) and 251 7.11% neutralizing antibodies (95% CI: 2.31 to 11.91%, p=0.004). Regarding participant age, each 252 one year increase in age was associated with -0.43 BAU/ml (95% CI: -0.86 to 0, p=0.049) and -253 0.25% decrease in neutralizing antibodies (95% CI: -0.38 to -0.12%, p<0.001) ( Table. 2). 254

Generally, IgG and neutralizing antibodies levels declined as more days passed after receiving the 256 second vaccine dose. Antibodies-duration adjusted smooth relationships with 95% confidence 257 intervals are presented in (Figure 3) . Diabetes and hypertensive status did not show considerable 258 deviation from the linear decline over time, nor did we notice any appreciable change in slope 259 between different subgroups. Regression estimates using IgM antibodies as the outcome also did not 260

show any significant differences between diabetics and non-diabetics (Supplemental Table S1 ). In 261 the interaction analyses, across all groups, being diabetic was consistently associated with lower IgG 262 levels as compared to non-diabetics (Supplemental Figure S1) . However, the interaction terms 263 between diabetes status and the other variables (age, gender, previous COVID-19 infection, BMI and 264 hypertension) were not powered to result in statistically significant p-values. 265 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint our data obtained from SARS-CoV-2 vaccinees are consistent, at least in part, with another study by 327

Lampasona et al. reporting that humoral immune response against SARS-CoV-2 in patients with 328 diabetes was present and superimposable, regarding timing and antibody titers, to that of non-diabetic 329 patients (32). However, we found that levels of RBD-specific IgG and neutralizing antibodies were 330 significantly lower in diabetics than non-diabetics which may be explained by the fact that 331 hyperglycemia and insulin resistance are known to induce several immune defects, such as 332 impairment in monocyte/macrophage and neutrophil function, reduced lymphocyte proliferative 333 responses, defective antigen presentation, and complement activation dysfunction (33). Our findings 334 of the lower humoral responses in vaccinees with T2DM are corroborated by Yelin et al. who found 335 that Pfizer BNT162b2 vaccination had relatively similar effectiveness across age groups (16-80 years 336 old), however, specific chronic comorbidities, such as T2DM, hypertension, chronic obstructive 337 pulmonary disease (COPD), and immunosuppression were inversely associated with vaccine efficacy 338 (34). 339

Next, we observed that SARS-CoV-2 IgG and neutralizing antibody levels did not differ significantly 340 among BNT162b2 vaccinees with regard to obesity levels, age, and gender. In partial agreement with 341 our findings, a study analyzing the antibody titers at 7 days after the second dose of BNT162b2 342 vaccine in a group of 248 healthcare workers reported that age and gender significantly impacted the 343 vaccination outcome as young female participants exhibited increased humoral immune responses 344 while BMI and hypertension did not seem to associate with difference in immune response to 345 vaccination (35). Pragmatically, we ought not rule out that studies of larger cohorts may unveil 346 statistically significant differences associated with age, gender, and obesity levels. 347

More importantly, we found that levels of SARS-CoV-2 IgG and neutralizing antibodies were 348 significantly higher in people who had previously had COVID-19 infection. This is comprehensible 349 as the persons who recovered from COVID-19 infection are expected to elicit efficient humoral 350 immunity due to the pre-existing memory B-cell responses to SARS-CoV-2 . In agreement, a large 351 cohort (n=1090) study of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients found that the S-352 RBD-specific IgG and neutralizing antibody levels were higher in individuals who were previously 353 infected with SARS-CoV-2 compared to those without prior infection. Based on these results, the 354 authors suggested that a single dose of BNT162b2 Pfizer-BioNTech vaccine was adequate for 355 individuals with prior SARS-CoV-2 infection, toward considering anti-S IgG antibody levels as well 356 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint potential for neutralizing capability of elicited antibodies (36). Similar findings were reported by 357 several other studies involving diverse cohorts of various sizes (37; 38). 358

This study has a number of limitations. First, the population examined were self-selected mostly by 359 word of mouth and recruitment advertisements. It is likely that the sample is over-representing co-360 morbid individuals who actively sought to know the antibody protection levels they have after 361 vaccination. Second, the regression analyses adjusted for a number of a priori confounders, however, 362 we cannot rule out potential residual confounding by severity of illness. For example, we could not 363 assess whether patients with severe uncontrolled diabetes or uncontrolled hypertension show lower 364 response to vaccine-induced humoral immunity. Third, the small sample size also limited our ability 365 to examine the effects among different subgroups. The interaction analyses were likely underpowered 366 to detect statistically significant differences between different strata. Fourth, the data presented 367 represent a cross-sectional analysis of the humoral response only, therefore, further studies will be 368 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2021. ; https://doi.org/10.1101/2021.07.23.21261042 doi: medRxiv preprint

An interactive web-based dashboard to track COVID-19 in real time

Clinical 454 characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait

Fasting Blood Glucose and 457 COVID-19 Severity: Nonlinearity Matters

Clinical characteristics and outcomes of 460 COVID-19 patients with diabetes mellitus in Kuwait

Innate immune activation in obesity

Impact 463 of Diabetes in Patients Diagnosed With COVID-19

Drexhage 465 H, Baldeón L. Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review

resistin and visfatin: the missing link between endocrine 468 metabolic disorders and immunity

The implication of proinflammatory cytokines in 470 type 2 diabetes

Cytokine Storm in COVID-19: The Current 472 Evidence and Treatment Strategies

Cytokine storm and COVID-19: a chronicle of pro-474 inflammatory cytokines

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England 479 journal of medicine 2020

BNT162b2 mRNA 481 SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers

Rodes-Guirao L. 484 A global database of COVID-19 vaccinations

Antibodies and B cell memory in viral immunity

Role of IgM and IgA 490 Antibodies in the Neutralization of SARS-CoV-2

CoV-2 with IgG from COVID-19-convalescent plasma

Human IgG and IgA responses to COVID-19 495 mRNA vaccines

Structure and function of immunoglobulins

How antibodies use complement to regulate antibody 499 responses

Jefferis R. Structure-function relationships in human immunoglobulins

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Human IgG and IgA responses to COVID-19 508 mRNA vaccines

Immunological 510 considerations for COVID-19 vaccine strategies

Immune Response to COVID-19 512 mRNA Vaccine-A Pilot Study

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare 515 workers

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Longitudinal observation and decline of 529 neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

COVID-19 mRNA vaccine induced antibody 535 responses against three SARS-CoV-2 variants

Antibody responses to the BNT162b2 mRNA vaccine in 538 individuals previously infected with SARS-CoV-2

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding 546 Domain by Structure-Guided High-Resolution Serology

Antibody response to multiple antigens 550 of SARS-CoV-2 in patients with diabetes: an observational cohort study

The Effects of Type 2 Diabetes 553 Mellitus on Organ Metabolism and the Immune System

Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient 556 age and comorbidities

Initial observations on age, gender, BMI 561 and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Antibody responses to the BNT162b2 mRNA vaccine in 565 individuals previously infected with SARS-CoV-2

Antibody response to first BNT162b2 dose in previously SARS-568

CoV-2-infected individuals

Antibody Responses in Seropositive Persons after a Single 574 Dose of SARS-CoV-2 mRNA Vaccine